Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

European Journal of Cancer

Volumn 61, Issue , 2016, Pages 111-121

  Roviello, Giandomenico ^a,b   Sigala, Sandra ^a   Sandhu, Shahneen ^c   Bonetta, Alberto ^d   Cappelletti, Maria Rosa ^b   Zanotti, Laura ^b   Bottini, Alberto ^b   Sternberg, Cora N ^f   Fox, Stephen B ^e   Generali, Daniele ^b,g  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Molecular Therapy and Pharmacogenomics Unit   (Italy)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d CREMONA HOSPITAL   (Italy)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^g UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Abiraterone acetate; Enzalutamide; Orteronel; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT;

BIBLIOGRAPHIC DATABASE; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; FOLLOW UP; HUMAN; MALE; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; DISEASE FREE SURVIVAL; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84965149689     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.04.002     Document Type: Review

References (40)

1. C. Neppl-Huber, M. Zappa, J.W. Coebergh, E. Rapiti, J. Rachtan, B. Holleczek, et al. EUNICE Survival Working Group Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths Ann Oncol 23 5 2012 May 1325 1334
2. D. Mukherji, A. Omlin, C. Pezaro, A. Shamseddine, and J. de Bono Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics Cancer Metastasis Rev 33 2-3 2014 Sep 555 566
3. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, and et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
4. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, and et al. AFFIRM investigators increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
5. C.J. Ryan, M.R. Smith, J.S. de Bono, and et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
6. T.M. Beer, A.J. Armstrong, D.E. Rathkopf, Y. Loriot, C.N. Sternberg, C.S. Higano, et al. the PREVAIL Investigators Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 2014
7. K. Fizazi, R. Jones, S. Oudard, E. Efstathiou, F. Saad, R. de Wit, and et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5 J Clin Oncol 33 7 2015 Mar 1 723 731
8. F. Saad, K. Fizazi, V. Jinga, E. Efstathiou, P.C. Fong, L.L. Hart, et al. ELM-PC 4 investigators Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial Lancet Oncol 16 3 2015 Mar 338 348
9. Á. Pinto Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer Cancer Biol Ther 15 2 2014 Feb 149 155
10. Y. Chen, N.J. Clegg, and H.I. Scher Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol 10 2009 981 991
11. C. Massard, and K. Fizazi Targeting continued androgen receptor signaling in prostate cancer Clin Cancer Res 17 2011 3876 3883 PMID:21680543
12. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
13. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, and et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
14. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
15. W.G. Cochran The combination of estimates from different experiments Biometrics 10 1954 101 129
16. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
17. N.D. Shore, S. Chowdhury, A. Villers, L. Klotz, D.R. Siemens, Phung, and et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study Lancet Oncol 2016 Jan 13 pii: S1470-2045(15) 00518-5
18. D.F. Penson, A.J. Armstrong, R. Concepcion, N. Agarwal, C. Olsson, L. Karsh, and et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial J Clin Oncol 2016 Jan 25
19. K. Fizazi, H.I. Scher, A. Molina, C.J. Logothetis, K.N. Chi, R.J. Jones, et al. COU-AA-301 Investigators Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 10 2012 Oct 983 992 Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. Lancet Oncol. 2014 Aug;15(9):e365
20. C.J. Ryan, M.R. Smith, K. Fizazi, F. Saad, P.F. Mulders, C.N. Sternberg, et al. COU-AA-302 Investigators Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 16 2 2015 Feb 152 160
21. C.J. Logothetis, E. Basch, A. Molina, K. Fizazi, S.A. North, K.N. Chi, and et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial Lancet Oncol 13 12 2012 Dec 1210 1217
22. D.E. Rathkopf, M.R. Smith, J.S. de Bono, C.J. Logothetis, N.D. Shore, P. de Souza, and et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) Eur Urol 66 5 2014 Nov 815 825
23. Y. Loriot, K. Miller, C.N. Sternberg, K. Fizazi, J.S. De Bono, S. Chowdhury, and et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial Lancet Oncol 16 5 2015 May 509 521
24. T.M. Beer, A.J. Armstrong, C.N. Sternberg, C.S. Higano, D.E. Rathkopf, Y. Loriot, and et al. Enzalutamide (ENZA) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): final analysis of the phase 3 PREVAIL study J Clin Oncol 33 2015 (suppl; abstr 5036)
25. C. Ndibe, C.G. Wang, and G. Sonpavde Corticosteroids in the management of prostate cancer: a critical review Curr Treat Options Oncol 16 2 2015 Feb 6
26. N. Agarwal, G. Di Lorenzo, G. Sonpavde, and J. Bellmunt New agents for prostate cancer Ann Oncol 25 9 2014 Sep 1700 1709
27. M.A. Titus, M.J. Schell, F.B. Lih, and et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin Cancer Res 11 2005 4653 4657
28. P.R. Dillard, M.F. Lin, and S.A. Khan Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol Mol Cell Endocrinol 295 2008 115 120
29. J. Edwards, N.S. Krishna, K.M. Grigor, and et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer Br J Cancer 89 2003 552 556
30. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
31. G. Roviello, R. Petrioli, L. Laera, and E. Francini The third line of treatment for metastatic prostate cancer patients: option or strategy? Crit Rev Oncol Hematol 2015 May 21 pii: S1040-8428(15) 00087-6
32. E. Francini, R. Petrioli, and G. Roviello No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide Expert Rev Anticancer Ther 2014 Aug 19 1 6
33. E. Francini, and G. Roviello How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue Tumour Biol 2014 May 30
34. R. Petrioli, E. Francini, L. Laera, A.I. Fiaschi, R. Ponchietti, and G. Roviello Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate Cancer Chemother Pharmacol 2015 Jun 17
35. C.J. Pezaro, A.G. Omlin, A. Altavilla, and et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents Eur Urol 66 2014 459 465
36. R. Petrioli, E. Francini, and G. Roviello Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol 6 5 2015 99 103
37. C.N. Sternberg, D. Castellano, G. Daugaard, L. Géczi, S.J. Hotte, P.N. Mainwaring, et al. Abiraterone Global EAP Investigators Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial Lancet Oncol 15 11 2014 Oct 1263 1268 Erratum in: Lancet Oncol. 2014 Nov;15(12):e528
38. O. Caffo, U. De Giorgi, L. Fratino, G. Lo Re, U. Basso, A. D'Angelo, and et al. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme BJU Int 115 5 2015 May 764 771
39. A.M. Joshua, N.D. Shore, F. Saad, K.N. Chi, C.A. Olsson, U. Emmenegger, et al. Enzalutamide Expanded Access Study Investigators Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America Prostate 75 8 2015 Jun 836 844
40. R. Iacovelli, E. Verri, M. Cossu Rocca, G. Aurilio, D. Cullurà, O. De Cobelli, and et al. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer Eur J Cancer 2015 Jul 10 pii: S0959-8049(15) 00621-8